Showing results (201-210 of 438) with videos related to
Sort By:
Pageof 44
International Journal of Environmental Research and Public Health|January 12, 2021
The Economic Impact of Rectal Cancer: A Population-Based Study in ItalyAnna Gigli, Silvia Francisci, Giulia Capodaglio, et al.European Journal of Cancer (Oxford, England : 1990)|December 21, 2021
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancerGiovanni Randon, Rossana Intini, Chiara Cremolini, et al.International Journal of Cancer|June 12, 2020
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancerCindy Neuzillet, Andrea Casadei-Gardini, Bertrand Brieau, et al.Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.European Journal of Cancer (Oxford, England : 1990)|May 25, 2023
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European CohortJulien Taïeb, Lina Sayah, Kathrin Heinrich, et al.Clinical Colorectal Cancer|August 29, 2018
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR StudyMarta Schirripa, Giuseppe Pasqualetti, Riccardo Giampieri, et al.Nature Medicine|March 17, 2026
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialKohei Shitara, Hirokazu Shoji, Nicola Fazio, et al.Journal for Immunotherapy of Cancer|April 21, 2023
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE studyRoberto Moretto, Daniele Rossini, Aurélie Catteau, et al.Anticancer Research|March 28, 2023
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE IndexMara Persano, Margherita Rimini, Toshifumi Tada, et al.European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studiesR Moretto, D Rossini, Mariam Grazia Polito, et al.Pageof 44